Researchers create comprehensive database of head and neck cancers

January 07, 2021

FOR IMMEDIATE RELEASE

In what is believed to be the most comprehensive molecular characterization to date of the most common type of head and neck cancer, researchers from the Johns Hopkins departments of
Their deep-dive investigation of HPV-negative head and neck squamous cell carcinomas (HNSCCs), described in the Jan. 7 issue of the journal
, involved tumors from 108 patients who had not yet received cancer treatment, and 66 samples of healthy tissue surrounding the tumors. The study systematically catalogued HPV-negative HNSCC-associated proteins, phosphosites (areas where they are modified by phosphate groups) and signaling pathways, finding three distinct subtypes of HNSCCs.

HNSCCs arise in the cells that line the upper aerodigestive tract, including the lips, mouth, tongue, nose, throat, vocal cords, and part of the esophagus and windpipe. The first subtype of HNSCC identified by researchers, dubbed CIN, showed the worst prognosis. It was associated with the larynx, a strong history of smoking and high instability of chromosomes. Because this subtype was associated with frequent aberrations of the CCND1 and CDKN2A genes, and high activity of the enzymes CDK4 and CDK6, this type of cancer may respond best to anti-cancer drugs called CDK4/6 inhibitors.

The second subtype, dubbed Basal, showed protein elevations of several basal factors, the most basic set of proteins needed to activate gene transcription. It was characterized by high activity in a signaling pathway called EGFR (epidermal growth factor receptor) and high expression of molecules called AREG and TNFA, which attach to the EGFR tumor protein. Therefore, researchers say, these cancers may respond best to anti-cancer drugs called monoclonal antibodies that are aimed at EGFR.

The third subtype, called Immune, was found among tumors in people who did not smoke and showed high expression of multiple immune checkpoint proteins. Researchers say these tumors may best respond to anti-cancer drugs called immune checkpoint inhibitors. Overall, 32% of CIN tumors, 62% of Basal tumors and 83% of Immune tumors had high potential for the suggested treatments.

Researchers also found two modes of activation of EGFR, suggesting a new strategy to stratify HNSCCs based on the number of molecules bound to EGFR, for effective treatment with monoclonal antibody drugs that enlist the natural immune system to fight cancer. Additionally, they noted that widespread deletion of immune modulatory genes among these cancers accounts for a loss of ability to produce an immune response.

"This study extends our biological understanding of HPV-negative HNSCCs and generates therapeutic hypotheses that may serve as the basis for future studies and clinical trials toward molecularly guided precision medicine treatment of this aggressive cancer type," says

The three subtypes and suggested treatments "are quite major findings," says

" Hui Zhang, Ph.D., co-principal investigator of the study, professor of pathology and oncology, and director of the

Researchers used the most advanced genomic and proteomic technologies available to tease out HNSCC proteogenomic characteristics, defined as genetic makeup (genomics), chemical modifications to DNA (epigenomics), messenger RNA located in cells that serves as a template to make proteins (transcriptomics), and proteins (proteomics) and their modification by phosphate groups (phosphoproteomics), a modification known to regulate protein functions by switching on or off. The work was completed as part of the National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium (CPTAC), a national effort to better understand cancers through proteogenomics.
-end-
HNSCC is the sixth most common malignancy worldwide, and it can be classified into HPV-associated and HPV-negative subtypes. About 75% of all HNSCCs are HPV-negative; they have distinct molecular profiles and significantly worse prognoses. Most patients are treated with surgery, chemotherapy and radiation. Targeted agents, including an EGFR monoclonal antibody inhibitor and two PD-1 immune checkpoint inhibitors, have been approved by the Food and Drug Administration, but overall response rates have been moderate. Prior to the study, a complete understanding of how genetic aberrations drive tumor types has remained elusive, and the translation of genomic and transcriptomic findings into improved HNSCC treatment has been limited.

The work was supported by the National Cancer Institute Clinical Proteomic Tumor Analysis Consortium (grants U24 CA210954, U24 CA210985, U24 CA210972, U24 CA210979, U24 CA210986, U24 CA214125, U24 CA210967, and U24 CA210993); a Cancer Prevention Institute of Texas (CPRIT) award (grant RR160027); the Translational Breast Cancer Research Training Program (grant T32 CA203690); and the McNair Foundation.

Other study co-authors were Lijun Chen, Rodrigo Vargas Eguez, Michael Schnaubelt, Qing Kay Li, David J. Clark, Yingwei Hu, Liwei Cao, Jianbo Pan, Yuefan Wang, Kyung-Cho Cho, Zhen Zhang and Jiang Qian of Johns Hopkins. Other investigators contributing to the study were from Baylor College of Medicine, Houston; Washington University, St. Louis; the University of Michigan; the Broad Institute of Massachusetts Institute of Technology and Harvard; the Icahn School of Medicine at Mount Sinai, New York; Sylvester Comprehensive Cancer Center, Miami; the University of Miami Miller School of Medicine; Gladstone Institutes, San Francisco; ESAC, Inc., of Rockville, Maryland; the National Cancer Institute; Vanderbilt University School of Medicine, Nashville; the University of Texas M.D. Anderson Cancer Center, Houston; Pomeranian Medical University, Poland; the International Institute for Molecular Oncology, Poland; the University of Medical Sciences, Poland; the Institute of Human Genetics Polish Academy of Sciences; Pozna? University of Medical Sciences, Poland; and Massachusetts General Hospital, Boston.

Johns Hopkins Medicine

Related Neck Cancer Articles from Brightsurf:

Head and neck cancer patients benefited from Affordable Care Act
The rate of uninsured patients with head and neck cancers was 'significantly reduced' following the implementation of the federal Patient Protection and Affordable Care Act (ACA).

Insurance coverage among patients with head/neck cancer after ACA
Researchers investigated the association between the Affordable Care Act and changes in the percentage of patients with insurance among 130,000 people with head and neck cancer across varying socioeconomic and demographic backgrounds.

Skin cancer above the neck more likely to spread, research shows
Forty-five patients with new diagnoses of MM were investigated over a period of 6 months and were divided into two groups of patients, with above neck MM and below neck MM.

How cigarette smoke makes head and neck cancer more aggressive
A change in the tumor metabolism due to tobacco exposure could open new treatment avenues in head and neck cancer.

Testing therapies on mini-tumors of head and neck cancer
Head and neck cancer is an aggressive type of cancer that often recurs, despite patients undergoing harsh treatments.

Comparing financial burdens of head and neck cancer with other cancers
Head and neck cancer is expensive to treat and the disease can create long-term health needs.

Opioid use and misuse following treatment for head and neck cancer
Six months after treatment ended, 7 percent of patients remained on opioid pain medications.

Study: Immunotherapy better than chemotherapy for subtype of head and neck cancer
A randomized clinical trial involving 97 medical centers in 20 countries, including Moores Cancer Center at UC San Diego Health, found that treating patients with head and neck cancer with the immunotherapy drug pembrolizumab is more effective and less toxic than standard chemotherapy.

Immunotherapy keeps some advanced head and neck cancer patients alive for over three years
A new immunotherapy can greatly extend the lives of a proportion of people with advanced head and neck cancer, with some living for three years or more, a major new clinical trial reports.

Head and neck cancer survivors at increased risk of suicide
Despite improved survival rates among cancer patients, the risk of death by suicide remains high, especially among those treated for head and neck cancers.

Read More: Neck Cancer News and Neck Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.